News & Views - Telix Pharmaceuticals Limited | Telix Pharmaceuticals Limited

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Telix Appoints David Gill as Chair

Telix today announces that David Gill has been appointed Chair of the Board, effective immediately.

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

Telix today announces its financial results for the period ended June 30, 2026.

Telix H1 2026 Results: Investor Webcast Notification

Telix today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.

EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer

Telix today announces publication of long‑term clinical outcomes from an investigator‑led study evaluating TLX400‑Tx, its lead fibroblast activation protein (FAP)-targeted therapy candidate, in patients with advanced or metastatic medullary thyroid carcinoma (MTC).

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Telix today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evaluate lesion concordance between 68Ga-PSMA-PET[5] and multi-time point SPECT[6] imaging for patient selection using a “theranostic” approach.

PSMA-PET imaging for prostate cancer: Exploring gallium-68 in clinical practice

Telix spoke with a panel of global experts to examine the rapid evolution of gallium-68 (68Ga) PSMA-PET imaging in prostate cancer and to ask where the technology goes next.

Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Txfor Renal Cancer

Telix today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan)in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in patients with relapsed or recurrent ccRCC.

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

Telix today announced completion of patient enrollment in the pivotal Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11[1]) for prostate cancer imaging in Japanese patients.